louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03405051: Hypokalemia in Hospitalized Patients for Heart Failure in the Therapeutic Cardiac Failure Unit
Official title: Hypokalemia in Hospitalized Patients for Heart Failure in the Therapeutic Cardiac Failure Unit: Morbidity-mortality Impact
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
Keywords: hypokalemia
cardiac failure
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2018-01-19
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with congestive heart failure admitted to the Heart Failure Unit in the Mercy hospital (CHR Metz-Thionville).

Brief summary: Hypokalemia is very common in heart failure patients. Deleterious effects have been report on the cardiovascular system. Most of the clinical data concerning this ionic trouble are based on post-hoc study and some findings seemed disjointed.

Detailed description: This study tried to describe hypokalemia impact during hospital stay in hospitalized patients with heart failure and particularly on mortality and re-hospitalization.

Eligibility criteria: Inclusion Criteria:

* Hospitalized patient in the Therapeutic Cardiac Failure Unit in the CHR Metz-Thionville
* Patient with congestive heart failure

Exclusion Criteria:

* None

Primary outcomes:
measure: Composite of death and re-hospitalization
timeFrame: Month 3
Secondary outcomes:
measure: Death
timeFrame: Month 3
measure: Re-hospitalization
timeFrame: Month 3
measure: Length of stay
timeFrame: Month 3
measure: Incidence of hypokalemia
timeFrame: Month 3
measure: Prevalence of hypokalemia
timeFrame: Month 3
Other outcomes:
Locations:
city: Metz
country: France
facility: CHR Metz-Thionville
Study officials:
References:
Clinical trial NCT01777451: Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Official title: Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Whole Body Imaging
Magnetic Resonance Imaging
Neurofibromatosis 1
Diffusion Magnetic Resonance Imaging
Peripheral Nerve Sheath Tumors, Malignant
Keywords: Whole Body Imaging
Magnetic Resonance Imaging
Neurofibromatosis 1
Diffusion Magnetic Resonance Imaging
Peripheral Nerve Sheath Tumors, Malignant
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2013-01-28
Enrollment: 30
Sex: ALL
Minimum age (years): 6
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with a clinically proven neurofibromatosis type 1 can be included.

Brief summary: Whole body MRI will be performed in patients with neurofibromatosis Type 1

PURPOSE 1:

To determine the total tumor load (neurofibroma) and to diagnose plexiform neurofibromas or malignant peripheral nerve sheath tumors. All patients will be scanned two years after the baseline whole body MRI to investigate to investigate the changes of total tumor load.

PURPOSE 2: added value of diffusion weighted imaging in diagnosis of high-risk neurofibromas

PURPOSE 3 : to determine the apparent diffusion coefficient of the malignant nerve sheath tumors and neurofibroma.

PURPOSE 4 : correlation between histopathology of the surgically resected neurofibroma/malignant nerve sheath tumors and MRI findings


Eligibility criteria: Inclusion Criteria:

* Patients with neurofibromatosis type 1, between 6 and 50 years old

Exclusion Criteria:

* Patients who are not allowed to be scanned on MRI (contra-indications: pacemaker ed.)

Primary outcomes:
measure: Estimation of total tumor load and diagnosis of high-risk neurofibromas
timeFrame: 1 month
Secondary outcomes:
measure: To diagnose high-risk neurofibroma
timeFrame: 2 months
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospitals Leuven
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Steven Pans, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tucker T, Friedman JM, Friedrich RE, Wenzel R, Funsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009 Feb;46(2):81-5. doi: 10.1136/jmg.2008.061051. Epub 2008 Oct 17.
citation: Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar;250(3):665-73. doi: 10.1148/radiol.2503080700.
citation: Van Meerbeeck SF, Verstraete KL, Janssens S, Mortier G. Whole body MR imaging in neurofibromatosis type 1. Eur J Radiol. 2009 Feb;69(2):236-42. doi: 10.1016/j.ejrad.2008.10.024. Epub 2008 Dec 16.
Clinical trial NCT02752451: Cigar Box Arthroscopy: A Study of Non-Anatomic Arthroscopy Training
Official title: Cigar Box Arthroscopy: A Randomized Controlled Trial Validates Non-Anatomic Simulation Training of Novice Arthroscopy Skills
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Simulation Training
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2016-04-27
Enrollment: 24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Comparison of success rates of novice surgeons to attain proficiency in basic arthroscopy skills after receiving prior training with different simulation systems.

Detailed description: A non-anatomic set of training modules utilizing cigar boxes was developed at our institution to instruct residents in the basics of knee arthroscopy. Twenty-four medical students with no prior arthroscopic or laparoscopic experience were enrolled as subjects. Sixteen subjects were randomized to participate in four hours of either the cigar box arthroscopy trainer (CBAT) or a previously validated anatomic knee arthroscopy trainer (AKAT). The remaining eight subjects served as controls (CO). All subjects underwent a one-hour formalized training session provided by our orthopaedic sports faculty. Subjects' skills were assessed by one of two faculty members through repeated attempts at performing a diagnostic knee arthroscopy on a cadaveric specimen. Objective scores were given using the Basic Arthroscopic Knee Skill Scoring System. Total cost differences were also calculated.

Eligibility criteria: Inclusion Criteria:

* First or Second year medical student with no prior arthroscopy or laparoscopy training.

Exclusion Criteria:

* Having previously received education in arthroscopy or laparoscopy or handled these instruments.

Primary outcomes:
measure: Success rate in reaching a level of minimum proficiency
timeFrame: 1 hour
Secondary outcomes:
measure: Number of attempts to reach minimum proficiency
timeFrame: 1 Hour
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01447654: Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
Official title: INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypertrophic Cardiomyopathy
Keywords: Hypertrophic cardiomyopathy
Hypertrophic obstructive cardiomyopathy
Hypertrophy
Losartan
Angiotensin II receptor antagonist
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2011-10-06
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective The objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM).

Design The study is a randomized, placebo-controlled, double-blinded trial. The follow-up period is 12 months. 130 patients with HCM will be included in predefined subgroups. Genotype positive relatives with borderline hypertrophy (\> 13 mm) will also be included. Data on individuals with borderline hypertrophy will be analysed separately from the rest of the cohort.

Primary outcome Ventricular hypertrophy assessed as left ventricular mass and maximal wall thickness.


Eligibility criteria: Inclusion Criteria:

* Hypertrophic cardiomyopathy
* \> 18 years
* Sinus rhythm

Exclusion Criteria:

* EF \< 50 %
* Treatment with RAS-inhibitor
* Contraindications to losartan

Primary outcomes:
measure: Hypertrophy of left ventricle
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of cardiology, Rigshospitalet.
Study officials:
References:
citation: Axelsson A, Iversen K, Vejlstrup N, Ho CY, Havndrup O, Kofoed KF, Norsk J, Jensen M, Bundgaard H. Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Heart. 2016 Feb 15;102(4):285-91. doi: 10.1136/heartjnl-2015-308343. Epub 2015 Dec 9.
citation: Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, Ahtarovski K, Corell P, Havndrup O, Jensen M, Bundgaard H. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015 Feb;3(2):123-31. doi: 10.1016/S2213-8587(14)70241-4. Epub 2014 Dec 19.
Clinical trial NCT00805454: Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
Official title: A Phase I, Open-Label,Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Schizophrenia
Keywords: Healthy Volunteers
Phase I
Pet Scan
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Otsuka Pharmaceutical Co., Ltd.
First posted: 2008-12-09
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Primary purpose: BASIC_SCIENCE

Brief summary: Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.

Detailed description: Subjects will receive a dose of study medication and will undergo a PET scan at 4 hrs and 23.5 hours post dose. Subjects will remain in the clinic from Day-1 to Day 7 for PK sample collection and safety monitoring. Subjects will return to the clinic on Day 10 for a follow-up safety assessment.

Eligibility criteria: Inclusion Criteria:

* Males and non-child bearing potential females between 18 and 45 years of age, inclusive.
* BMI between 19 and 32 kg/m2, inclusive.

Exclusion Criteria:

* Condition or history which may present a safety concern to the subject or interfere with outcome variables.
* History of or current drug or alcohol abuse, hepatitis, AIDS, or drug allergy.
* Use of prescription, over-the-counter, or herbal medication, or vitamin supplements within 14 days or antibiotics within 30 days.
* Use of tobacco products or daily exposue to second hand smoke.
* Blood pressure higher than 140/90 mmHg or lower than 100/50 mmHg: heart rate outside 40 to 90 beats/minute.
* History of serious mental disorder.

Primary outcomes:
measure: Pharmacodynamic: Percent occupancy of D2 receptor, as judged by PET scan.
timeFrame: 10 days
Secondary outcomes:
measure: Measure safety: adverse events, vital signs, ECGs, and clinical laboratory tests
timeFrame: 30 days
Other outcomes:
Locations:
Study officials:
affiliation: Johns Hopkins University, Baltimore,MD 21287
name: Dean Wong, MD,PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: SNBL, Baltimore,MD 21201
name: Stephen Bart, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wong DF, Raoufinia A, Bricmont P, Brasic JR, McQuade RD, Forbes RA, Kikuchi T, Kuwabara H. An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol. 2021 May;77(5):717-725. doi: 10.1007/s00228-020-03021-9. Epub 2020 Nov 16.
Clinical trial NCT01400854: Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Official title: ERKENTNIS: Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Pain
Keywords: breakthrough cancer pain
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2011-07-22
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult cancer patients (in- or out-patients) that are suffering from breakthrough pain

Brief summary: Aim of this non-interventional study is to investigate the tolerability of Effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.

Detailed description: In addition to the effectiveness of Effentora® therapy, safety, general feasibility and the impact of therapy on the patients' quality of life are of interest.

Eligibility criteria: Inclusion Criteria:

* decision to start treatment with Effentora
* prescription in accordance with Summary of Product Characteristics (SmPC)
* personally signed and dated Informed Consent document

Exclusion Criteria:

* any subject considered unsuitable according to SmPC

Primary outcomes:
measure: pain relief
timeFrame: 4 weeks
Secondary outcomes:
measure: occurrence of adverse events
timeFrame: 4 weeks
measure: Change in level of breakthrough pain
timeFrame: 4 weeks
measure: presence of specific triggers for breakthrough pain
timeFrame: 4 weeks
measure: quality of life
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Cephalon GmbH
state: Bavaria
Study officials:
affiliation: Cephalon
name: Medical Department
role: STUDY_DIRECTOR
References:
Clinical trial NCT00320554: Motion Characteristics of the Foot and Ankle as Measured by Durometer Readings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Foot Motion Characteristics
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2006-05-03
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to determine the motion characteristics of the foot and ankle with a durometer as a method of measurement.

Detailed description: This study will assess and establish the motion characteristics of the foot and ankle with the use of a durometer as a measure of motion patterns.

The durometer is a device commonly used in materials testing that measures displacement through the use of a piezoelectric sensor configured to detect motion a in the form of a reflected wave back from the surface being tested.

Eligibility criteria: Inclusion Criteria: Logan student, staff, or faculty with no history of ankle injury; 2. Age 18 - 60 yoa Exclusion Criteria: 1. Logan student, staff, or faculty with no history of ankle surgery 1. No visual or vestibular condition that would affect balance; 2. Systemic illness that have an adverse effect on balance; 3. Local infection, injury or other malignancy affecting the lower extremity; 4. Any unstable joints of the lower extremity; 5. Any manipulation to the foot ankle joints within 48 hours; 6. Prescription or herbal muscle stimulants, relaxants, etc.; 7. Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractic
state: Missouri
Study officials:
affiliation: Logan College of Chiropractic
name: Dennis E. Enix, DC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01382654: Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Allergic Rhinitis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2011-06-27
Enrollment: 131
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objectives of this study were to:

* Examine the tolerability of two formulations and two dose concentrations of epinastine.
* Select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute scores of the Nasal Spray Evaluation Questionnaire (NSEQ) collected after each study drug administration and the subject preference ranking assessed at the completion of the study.
* Compare the preference of two formulations and two dose concentrations of epinastine compared to azelastine following a single dose of each in a randomized, double-blind, two-cohort, three-period crossover design.


Eligibility criteria: Inclusion Criteria:

* between ages 18-70
* history of SAR or PAR for 1 year
* mild symptoms

Exclusion Criteria:

* asthma or RAD
* respiratory tract infection within 14 days prior to screening

Primary outcomes:
measure: Overall preference rank at the completion of the study using the Overall Nasal Spray Evaluation Questionnaire (NSEQ)
timeFrame: 2 days
Secondary outcomes:
measure: Scores from each individual response from the NSEQ of all administered formulations (two formulations and two concentrations of epinastine and azelastine).
timeFrame: 2 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05865054: Vessel Wall Enhancement in Giant Cell Arteritis
Official title: Vessel Wall Enhancement in Giant Cell Arteritis: The VEGA Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Giant Cell Arteritis
Keywords: Temporal Arteritis
Juvenile Temporal Arteritis
Horton's Giant Cell Arteritis
Horton's Disease
Horton Giant Cell Arteritis
Horton Disease
Giant Cell Aortitis
Giant Cell Aortic Arteritis
Cranial Arteritis
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2023-05-18
Enrollment: 400
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be recruited from the ambulatory clinic, emergency department, or inpatient settings.

Brief summary: The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient diagnosed with giant cell arteritis (GCA; temporal arteritis).

Detailed description: After signing the consent form, participants will complete an MRI scan within 2 weeks of enrollment and fill out questionnaires related to their disease. Follow up visits and MRI scans may occur at 1-month, 6-months, 12-months after the initial MRI scan or at the time of relapse.

Eligibility criteria: Inclusion Criteria:

* Participant must be in one of the following groups:

  1. Suspected new diagnosis of GCA
  2. Suspected relapse of GCA (new or worsening symptoms attributed to active GCA) in patient with previously established diagnosis of GCA
* The participant must have (or previously had) cranial manifestations related to or concerning for GCA including: visual symptoms, headache, temporal artery tenderness, jaw claudication, scalp tenderness, or stroke
* Participant must be within 14 days of initiating or escalating systemic glucocorticoids (e.g., prednisone) OR have ongoing cranial symptoms concerning for active disease at time of baseline MRI.
* Participants who are receiving a clinically-indicated MRI at the time of enrollment may participate even if they meet exclusion criteria of creatinine clearance less than 30 ml/min or mild gadolinium allergy
* Participants must sign the informed consent form

Exclusion Criteria:

* Contra-indication to receiving MRI including:

  * Implanted medical devices, pacemaker and metallic foreign fragments inside body or orbit
  * Known gadolinium allergy
  * Estimated glomerular filtration rate less than 30 ml/min/1.73m2
* Claustrophobia
* Women who are pregnant or nursing

Primary outcomes:
measure: Vessel Wall Enhancement Score
timeFrame: Up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: 3400 Civic Center Blvd
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Rennie Rhee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00757354: A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty
Official title: A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis
Avascular Necrosis
Traumatic Arthritis
Rheumatoid Arthritis
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
Collaborators: name: Biomet U.K. Ltd.
First posted: 2008-09-23
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A clinical Evaluation to determine metal ion release from 4th generation metal-on-metal hip articulating surfaces in cementless total hip arthroplasty.

Detailed description: This evaluation is being conducted to investigate the extent of metal ion release and its incorporation into the surrounding tissue resulting from metal on metal articulating surfaces in cementless total hip arthroplasty.

The amount of metallic ions released post operatively will be assessed by the concentration of Cobalt, Chromium and Molybdenum present in urine and analysed by I.C.P.M.S. (Inductive Coupled Plasma Mass Spectroscopy). The amounts of metallic ions released will be related to the hip function and range of motion measured pre-operatively and post-operatively. Secondary performance of the metal-on-metal articulation will be determined by radiographic evaluation and incidence of complications / revision rates.

Eligibility criteria: Inclusion Criteria:

* Subjects selected for this Evaluation will be grouped by initial diagnosis into one of the following diagnostic groups:

  * Non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and traumatic arthritis.
  * Rheumatoid arthritis.
* Selection of subjects for this Evaluation should include the following considerations:

  * Patients under 70 years of age.
  * Willing to return for follow-up evaluations.
  * No bias to sex.

Exclusion Criteria:

Primary outcomes:
measure: concentration of Cobalt, Chromium and Molybdenum ions in urine
timeFrame: various follow-up visits
Secondary outcomes:
measure: harris Hip Score, oxford hip, WOMAC and SF-12
timeFrame: various follow-up visits
Other outcomes:
Locations:
city: Bristol
country: United Kingdom
facility: Avon Orthopaedic Centre
Study officials:
affiliation: Avon Orthopaedic Centre
name: Evert J Smith, FRCS
role: PRINCIPAL_INVESTIGATOR
References: